Brazil approves Celltrion Pharm’s syringe facility

The S.Korean pharmaceutical company aims to expand its CMO business for syringes for domestic and foreign companies

Celltrion Pharm's Cheongju plant in South Korea
Celltrion Pharm's Cheongju plant in South Korea
Jae-Young Han 1
2023-02-20 14:48:34 jyhan@hankyung.com
Bio & Pharma

Celltrion Pharm Inc., a South Korean biopharmaceutical company, said on Monday it received certification from Brazil’s health regulator for its pre-filled syringe production facility.

The company said it passed an inspection by Brazil’s National Health Surveillance Agency (ANVISA) at the end of last year at its plant in Cheongju, South Korea. The certification will allow Celltrion to produce and supply syringes to South America.

Celltrion also said it plans to undergo inspections by authorities in Japan and the US this year.

The company's syringe facility received approval from both Korea's Ministry of Food and Drug Safety and the EU in 2021, and started commercial production of autoimmune disease treatments Remsima SC and Yuflyma last year.

A Celltrion official said the company aims to expand its contract manufacturing business for syringes for domestic and foreign companies targeting the global market, and continue to grow through portfolio expansion.

Write to Jae-Young Han at jyhan@hankyung.com
##Celltrion Pharm prefilled syringe ##Celltrion PFS Brazil Certification #korea celltrion brazil #celltrion syringe brazil #celltrion south america

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion's Yuflyma Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosimilar of Humira (active ingredient: adalimumab), an autoimmune disease treatment developed by AbbVie of the US.Currently, the So

Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year

Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year

Celltrion's Remsima South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to treat autoimmune disease, in Brazil, the largest pharmaceutical market in Latin America.The company will supply in the first half

Celltrion applies for FDA approval for Remsima SC

Celltrion applies for FDA approval for Remsima SC

Celltrion's Remsima Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoimmune disease treatment.Remsima SC (infliximab) is a self-injectable drug developed as a subcutaneous injection formulation.A C
(* comment hide *}